P
Polyneuron Pharmaceuticals
Accurate treatment of autoimmune disorders
About Polyneuron Pharmaceuticals
Polyneuron Pharmaceuticals is a pioneering biotech company focused on developing innovative treatments for autoimmune diseases of the nervous system. The company operates in the pharmaceutical and biotechnology market, primarily serving patients with rare and debilitating autoimmune disorders. Polyneuron's core technology platform involves the chemical design of injectable glycopolymers that selectively eliminate pathogenic autoantibodies, offering a novel therapeutic approach that is both effective and safe. The company's business model revolves around the research, development, and commercialization of these glycopolymer-based drugs. Revenue is generated through the successful development and eventual market launch of these therapies, as well as potential partnerships and licensing agreements with larger pharmaceutical companies. Polyneuron's current pipeline includes treatments for multifocal motor neuropathy (MMN) and anti-MAG neuropathy, among others. The company is also exploring applications in ABO incompatible organ and stem cell transplantation. Keywords: autoimmune diseases, glycopolymers, nervous system, biotechnology, rare diseases, immunotherapy, drug discovery, MMN, anti-MAG neuropathy, transplantation.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2014
- Headquarters
- Basel, Switzerland
- Employees
- 4
- Open positions
- None listed
- Dealroom signal
- 57.6/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Neurology, Autoimmune, Immune System, Spinout, Disease, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Sep 2020 | $14M | $110M | Sofinnova Partners · NEA | — |
| SERIES A✓Equity / VC | Mar 2019 | $22M | $88M | EVA Basel · ZKB - Zürcher Kantonalbank · NEA · Sofinnova Partners | — |
Growth signals
Latest recorded traffic for Polyneuron Pharmaceuticals is 3.2K monthly website visits, up 1500% over the last three months. Polyneuron Pharmaceuticals's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
Venture Kick
ZKB - Zürcher Kantonalbank
EVA Basel
Series A2 investors entered at this stage
Other known investors4 additional known investors
University of Basel
BaseLaunch
HBM Partners
VentureLab
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Polyneuron Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Polyneuron Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.